Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.

CONCLUSIONS: The results confirm the dominant role of CA125 for identifying malignancy, and suggest that other markers (HE4, CA72.4, CA15.3 and LAP) may help to distinguish between stage I and stage II-IV malignancies. However, further research is needed, also to investigate the added value over clinical and ultrasound predictors of malignancy, focusing on the differentiation between subtypes of malignancy. PMID: 32994054 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32994054?dopt=Abstract

Source: Gynecologic Oncology - September 25, 2020 Category: Cancer & Oncology Authors: Landolfo C, Achten ETL, Ceusters J, Baert T, Froyman W, Heremans R, Vanderstichele A, Thirion G, Van Hoylandt A, Claes S, Oosterlynck J, Van Rompuy AS, Schols D, Billen J, Van Calster B, Bourne T, Van Gorp T, Vergote I, Timmerman D, Coosemans A Tags: Gynecol Oncol Source Type: research